Palvella Therapeutics’ (PVLA) Overweight Rating Reiterated at Stephens

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “overweight” rating restated by Stephens in a research note issued on Thursday,Benzinga reports. They presently have a $220.00 price objective on the stock. Stephens’ target price points to a potential upside of 90.57% from the company’s current price.

PVLA has been the subject of several other research reports. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. HC Wainwright raised their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Mizuho raised their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Chardan Capital reissued a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Price Performance

PVLA stock traded down $0.06 during trading on Thursday, hitting $115.45. The stock had a trading volume of 30,384 shares, compared to its average volume of 281,937. Palvella Therapeutics has a twelve month low of $20.20 and a twelve month high of $151.18. The stock has a market capitalization of $1.66 billion, a P/E ratio of -27.57 and a beta of -0.13. The company’s 50-day moving average price is $122.96 and its two-hundred day moving average price is $105.14.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, sell-side analysts expect that Palvella Therapeutics will post -5.43 EPS for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elaine J. Heron bought 2,400 shares of the business’s stock in a transaction on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the transaction, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Palvella Therapeutics during the first quarter worth $28,000. Group One Trading LLC increased its position in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the period. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics during the third quarter worth $28,000. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics during the third quarter worth $36,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth $167,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.